HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma.

AbstractObjective:
Pancreatic ductal adenocarcinoma (PDAC) is a lethal solid gastrointestinal malignancy with poor immune infiltration and a limited response to immunotherapy. The aim of our study was to explore the predictive value of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs), which are widely expressed in various tumor cells.
Methods:
Transcriptomic data with follow-up information were obtained from the GEO, TCGA and ArrayExpress. The Kaplan-Meier (KM) method and univariate Cox (UniCox) proportional hazard regression were used to show the survival outcomes of the groups. Immune infiltration was analyzed using the online databases TISCH, TISIDB, TIMER2.0, and TIDE as well as the R packages "estimate" and "GSVA." Mutation and functional enrichment analyses were conducted using the R packages "maftools," "clusterProfiler," and online repository HOME for Researchers. Finally, the results were validated in 79 samples from our cancer center.
Results:
Survival analysis using public databases and the FUSCC cohort indicated PDGFRA to be associated with prolonged overall survival (OS) (both p < 0.05). PDGFRA expression was highest in cancer-associated fibroblasts (CAFs) of PDAC, as validated in public databases and cell lines from our cancer center. The high expression of PDGFRA was associated with increased immune infiltration and potent T cell cytotoxicity in PDAC.
Conclusion:
In summary, high PDGFRA expression is associated with increased immune infiltration and prolonged OS. This finding might provide a new strategy for regulating immune cell infiltration in PDAC and improving the efficacy of immunotherapy.
AuthorsZijian Wu, Jin Xu, Rong Tang, Wei Wang, Bo Zhang, Xianjun Yu, Jiang Liu, Si Shi
JournalJournal of oncology (J Oncol) Vol. 2022 Pg. 4148805 ( 2022) ISSN: 1687-8450 [Print] Egypt
PMID35378770 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Zijian Wu et al.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: